Abstract. Throughout the past decade it has been recognized that dopaminergic medication administered to remedy motor symptoms in Parkinson's disease is associated with an enhanced risk for impulse control disorders and related compulsive behaviors such as hobbyism, punding, and the dopamine dysregulation syndrome. These complications are relatively frequent, affecting 6-15.5% of patients, and they most often appear, or worsen, after initiation of dopaminergic therapy or dosage increase. Recently, impulse control disorders have also been associated with subthalamic nucleus deep brain stimulation. Here we present a systematic overview of literature published between 2000 and January 2013 reporting impulse control disorders in Parkinson's disease. We consider prevalence rates and discuss the functional neuroanatomy, the impact of dopamine-serotonin interactions, and the cognitive symptomatology associated with impulse control disorders in Parkinson's disease. Finally, perspectives for future research and management of impulse control disorders in Parkinson's disease are discussed.
INTRODUCTION
Parkinson's disease (PD) is a progressive neurodegenerative disorder associated with a dopamine deficiency in the substantia nigra zona compacta and the ventral tegmental area in the midbrain causing abnormalities in movement, behavior, cognition, and emotion. Based on observations, James Parkinson first described the disorder as the "shaking palsy" in 1817. At that time, the senses and intellect of patients suffering from PD were believed to be unaffected by the disease [1] . Half a century later this assumption was revised by "the father of modern neurology" the French neurologist, Jean-Martin Charcot (1825-93), who suggested that the patients' state of mind is altered as the disease progresses. Nevertheless, in the general clinic, PD is still largely considered to be a movement disorder characterized by cardinal motor symptoms. According to the UK Brain Bank criteria for PD, presence of bradykinesia accompanied by at least one of the following: resting tremor, muscular rigidity, or postural instability, are required for a diagnosis of PD. Furthermore, at least three supportive criteria including: unilateral onset, excellent response to levodopa, resting tremor, severe levodopa-induced chorea, progressive disorder, levodopa response for over 5 years, persistent asymmetry affecting the side of onset most, or clinical course of over 10 years, must be present for a definite diagnosis.
Recently it has been established that even at early disease stages, PD is associated with cognitive impairments involving executive functions, working memory, impulse control, reversal learning, and decisionmaking, as well as emotional disturbances including depression, apathy, and anxiety causing a generally decreased quality of life [2] [3] [4] [5] [6] [7] [8] [9] . These non-motor manifestations of PD are to a great extent considered to result from a deficient dopaminergic innervation of limbic and prefrontal cortical brain regions following disease progression and are thus more pronounced at later disease stages. The syndromes may be further deteriorated by additional degeneration of the cholinergic, noradrenergic, and serotonergic neurotransmitter systems [10] [11] [12] [13] . Moreover, the medical and surgical treatments administered to relieve motor symptoms play complex roles via their indirect influence on unaffected brain regions potentially inducing cognitive and emotional dysfunctions. Weintraub and Nirenberg [8] , Crossman [14] , and Cools et al. [3, 4] recently discussed and presented results supporting the hypothesis that the behavioral syndromes depend on disturbances in the balance between the depleted dorsal striatum and the dominance of the relatively intact ventral striatum (including the nucleus accumbens) in early stages of the disease [3, 4, 6] . Though dopaminergic treatment in early PD relatively successfully recovers the normal function within the dorsal striatum involved in the sensory-motor circuit, the dopaminergic agents may "overdose" the ventral striatum, potentially resulting in affective disturbances and impulse control disorders (ICDs) [2] [3] [4] .
In the DSM-IV [15] , ICDs define a category of behavioral disorders characterized by recurrent maladaptive disinhibited behavior despite personal and relational consequences. Among these are pathological gambling, compulsive buying, hypersexuality, and binge eating. Since the early case report by Seedat et al. in 2000 [16] , it has been well documented that dopaminergic medication in a subgroup of PD patients induces ICDs and related compulsive disorders such as hobbyism, punding (i.e. various behavioral stereotypies), and the dopamine dysregulation syndrome (DDS) characterized by addiction-like self-medication of high doses of levodopa and short-acting dopamine agonists [8, 17] . The behavioral complications most often appear, or worsen, after initiation of D 2 /D 3 dopamine agonist therapy or dosage increase. In addition, symptoms tend to improve or disappear upon dosage decrease or discontinuation of the dopamine agonist treatment [8, [18] [19] [20] [21] [22] . The various syndromes affect 6-15.5% of PD patients [21, [23] [24] [25] [26] [27] [28] compared to a prevalence of ICDs of 1.1-1.6% in the general adult population [23, 24, 29, 30] . Moreover, ICDs have been associated with subthalamic nucleus deep brain stimulation (STN DBS) in subgroups of patients [23, [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] , where the results still present important controversies and disagreements [32, [42] [43] [44] . We return to this discussion later.
The etiology and pathogenesis of treatment-induced ICDs in PD remain unknown, though altered activity of the mesolimbic dopamine system has been suggested to be responsible for the phenomenon [23, 45] . Besides a high dose of dopamine agonists, additional risk factors associated with ICDs in PD include young age at PD onset (often in early forties), male gender, a novelty seeking personality, a personal or family history of addictive behaviors, and genetic factors [25, 28, [45] [46] [47] [48] [49] [50] [51] [52] [53] . A recent study added depressive symptoms to the list of important risk factors suggesting that the variance in the risk for developing ICDs is more attributable to the presence of depressive symptoms than to the above-mentioned factors [54] . This gained further support through a follow-up study describing 22 PD patients without ICDs at baseline, who at follow-up displayed behavioral symptoms significantly associated with an increase in depressive symptoms [55] . This is very interesting since depression is a major comorbidity in PD affecting 30-45% of patients, and in fact neuronal loss in the substantia nigra is significantly more pronounced in PD patients with comorbid depression compared to patients without depression [9] . Moreover, findings of improved mood disorder symptoms subsequently to treatment with dopamine agonists such as pramipexole serve additional backup to linking depression and ICDs in PD [9, 56] . For a further discussion of the epidemiology of ICDs in PD, we refer to a recent review by Weintraub and Nirenberg [8] .
Here we present a systematic review of literature published between 2000 and January 2013 reporting ICDs in PD [16, 18-22, 26, 27, 32-39, 41, 42, 45, 48, 51, 53-55, 57-132] . We consider prevalence rates and discuss distinctive forms of cognitive impairments associated with ICDs in PD. Furthermore, complementing the work of Weintraub and Nirenberg [8] , we add a discussion of the functional neuroanatomy and the dopamine-serotonin interactions implicated in ICDs in PD. Finally, we consider perspectives for future research and suggest possible implications for the management of ICDs in PD.
The studies included in this review have been identified through PubMed using the following search words: Parkinson's disease, impulse control disorders, impulsivity, cognition, and decision-making. The initial search strategy, which combined the words Parkinson's disease + impulse control disorders, identified 346 articles on January 18th 2013. We ended up including 98 empirical studies in the review among which 64 reports examining both PD patients with and without ICDs are presented in Table 1 below. Inclusion criteria were: Empirical studies examining PD patients who developed ICDs or experienced a worsening of ICD symptoms subsequent to initiation of dopaminergic medication or dosage increase. Exclusion criteria were: Reviews or other theoretical studies; studies focusing exclusively on other neurological diseases than PD such as multiple system atrophy or restless legs syndrome; studies on ICDs in unmedicated PD patients; studies focusing solely on treatment of ICDs in PD. However, we will return to the latter topic in our final discussion. A more extensive overview of all 98 studies is presented in the Supplementary Tables 1  and 2 .
SUMMARY AND DISCUSSION OF THE LITERATURE REVIEW
Based on the 98 reviewed reports, we conclude that ICDs occur relatively frequently in PD secondary to dopaminergic therapy. In total 17,286 PD patients were examined during 2000 and January 2013, and in this material 2,455 (14.2%) displayed prior or current symptoms of ICDs during dopamine replacement therapy. However, evaluating prevalence and characteristics of ICDs in PD, we only considered epidemiological studies suitable for this purpose. We reviewed 29 epidemiological studies describing a total of 14,929 patients with PD, including 1,495 patients with ICDs, which corresponds to a mean overall prevalence of 10% across different cultures. Pathological gambling and hypersexuality appear to be the most prevalent ICDs reported equally frequent in 518 (3.5%) and 524 (3.5%) of the 14,929 PD patients with ICDs, respectively. Binge eating was observed in 383 patients (2.6%) and compulsive buying in 374 patients (2.5%). Related compulsive conditions such as punding and hobbyism were reported in 549 patients (3.7%) and DDS in 53 (0.4%), see Fig. 1 . In total 377 patients reported symptoms of more than one ICD (2.5%).
The prevalence estimates are based on information available in the epidemiological studies in spite of the fact that not all of them assess all types of ICDs and compulsive disorders. Particularly, information on DDS is often not reported, and some papers lack information on which specific types of ICDs patients experienced. Thus, the true prevalence rates might be somewhat higher, which is in fact what Cilia and van Eimeren [133] summarizes on the basis of the DOMIN-ION study by Weintraub et al. [26] . Moreover, a very recent study in Finnish PD patients reports frequencies of pathological gambling and hypersexuality amounting to 8.8% and 22.8%, respectively [54] , whereas pathological gambling as deviant from other studies was only prevalent in 0.7% of Turkish PD patients, since gambling is illegal in Turkey [125] . This suggests that cultural differences might exist. Interestingly though, the prevalence rates in Asian samples were almost similar to prevalences in Western samples. Lim et al. [99] demonstrate that approximately 15% of PD patients in Malaysia display symptoms of ICDs relative to approximately 14% reported by Weintraub et al. on the basis of the largest cohort to date of 3,090 North American and Canadian PD patients [26] . Thus, it seems that the overall prevalence of ICDs in Asian and Western PD populations are comparable. Instead it seems that the most noticeable cultural difference is the relatively lower doses of dopamine agonists used in Asian samples compared to Western samples [99] . According to Lim et al. [99] , piribedil, which like pramipexole and ropinirole is selective for D 2 /D 3 dopamine receptors, is the most available dopamine agonist in Asian countries and this compound has also been associated with ICDs [99] . Nevertheless, in the Malaysian sample where piribedil accounted for approximately two thirds of the dopamine agonist usage, only ropinirole and pramipexole were significantly associated with ICD symptoms [99] .
Almost all PD patients with ICDs were treated with dopaminergic medication at the time of examination. The majority received a combination of levodopa and dopamine agonists. The most frequently used direct D 2 /D 3 dopamine agonists were pramipexole, ropinirole, and pergolide, and generally, the daily dose of dopaminergic medication was higher in patients with ICDs. Based on the epidemiological studies, the mean total levodopa equivalent daily dose (LEDD, levodopa and dopamine agonists) in PD patients with ICDs was 1,030 mg/day compared to a total LEDD in PD patients without ICDs of only 679 mg/day. The mean dopamine agonist LEDD was 243 mg/day in PD patients with ICDs compared to 132 mg/day in PD patients without ICDs. It is important to note, however, that LEDDs are most likely calculated based on different formulas, which complicates a direct comparison of LEDDs across studies [134] .
Overall, ICD symptoms predominantly occurred subsequent to treatment initiation or dosage increase, and seemed particularly related to the effects of the D 2 /D 3 dopamine agonists [20, 22, 59, 63, 65, 69, 71, 72, 74, 84, 85, 88] . This tendency is reflected in PDI: 64 (7) PDI: 59 (7) PG: 1 Illustrates the number of PD patients with ICDs across the specific kinds of ICDs: pathological gambling; hypersexuality; binge eating; compulsive buying; punding; and dopamine dysregulation syndrome. In total 377 patients reported having more than one ICD (2.5%). Hence, the sum of patients across ICDs (2,289) is larger than the total number of patients (1, 495) in the in the epidemiological studies reporting ICDs, since those with multiple ICDs are counted in all respective specific ICDs. Furthermore, the prevalence of DDS is probably underestimated, since information on DDS was unavailable in many of the reviewed report.
a higher frequency of ICDs of up to 17.1% among PD patients treated with dopamine agonists relative to 6.9% in patients not treated with dopamine agonists [26] . Generally, ICD symptoms improved or resolved after reduction or discontinuation of dopamine agonist therapy [18-22, 38, 48, 58, 62, 66, 67, 70-72, 84, 88, 89] , even when increasing levodopa dose as compensation for the lacking agonist treatment [81, 88] . Nevertheless, in most cases described it remains unclear whether ICD onset is a direct result of treatment initiation (or increase) or a consequence of prolonged dopaminergic therapy. Furthermore, most likely individual differences in PD symptomatology, age at disease onset, gender, personality, and psychiatric history influence the treatment-induced ICDs to an unknown degree. In addition, ICDs were already present prior to PD onset or treatment initiation in at least 28 patients (1.1%), a frequency corresponding to the prevalence of ICDs in the general population. These patients reported a worsening of symptoms following medication. Moreover, at least 58 (2.4%) PD patients with ICDs had a prior history of substance use disorders, while at least 179 (7.3%) and 79 (3.2%) patients with comorbid ICDs reported current or prior symptoms of a mood disorder or anxiety, respectively. Unfortunately, such details of information are simply not available in all included reports. Hopefully, the new screening instruments discussed by Weintraub and Nirenberg [8] may contribute to solving some of these issues in the future. The presented findings support the concept of treatment-induced ICDs in PD, which we will discuss in a neuro-cognitive perspective taking distinct brain regions, dopamine-serotonin interactions, and cognitive impairments into account.
THE FUNCTIONAL ROLE OF THE SUBTHALAMIC NUCLEUS IN ICDS IN PD
In the reviewed literature, it has been reported that a minimum of 86 patients with DBS in STN experienced occurrence, worsening, or no improvement of ICD symptoms following surgery [32, 33, 36, 37, 39, 42, 93, 118] , which corresponds to 3.5% of patients with ICDs. In contrast, ICD symptoms declined or were fully alleviated in at least 36 other cases (corresponding to 1.5% of patients with ICDs) upon DBS in STN, an effect, which is most likely related to the marked reduction in dopaminergic medication following DBS [32, 35, 37, 38, 40, 41, 64] . These deviating results strongly suggest that STN DBS influences both motor and non-motor functioning in PD in complex ways via its neuronal network connections. It remains open to speculation whether the discrepancies relate to the coordinates of stimulation or alternatively result from changes of the basal tonus of endogenous or exogenous dopamine in the basal ganglia-cortical loops [135] . One assumption might be that stimulation of the ventromedial STN through its close connection to the nucleus accumbens via the ventral pallido-medial STN neuronal loop potentially induces ICD symptoms, since the ventral striatum, and the nucleus accumbens in particular, is crucial in impulse control, motivational processes, and addictive behaviors [38] . Understanding the underlying mechanisms behind these issues is further complicated by different frequencies of stimulations leading to very different outcomes probably influencing both the ventromedial and lateral STN. Contrasting incidences have been reported where STN DBS has not only been linked to increased impulsivity and ICDs [44, 136] , but also to lack of motivation and even severe apathy and anhedonia [9, 137] . According to Tang and Strafella [9] and Volkmann et al. [138] , apathy, often co-occurring with depression, is one of the most common adverse effects of STN DBS documented in 24.6% of PD patients three years after surgery. However, a decrease in apathy severity within 3-6 months after surgery has been observed, indicating that perhaps apathy is only related to medication withdrawal or DBS itself in the immediate postoperative period. This suggests, that apathy could be a consequence of disease progression as well, that might be relieved by dopamine replacement therapy [9, 56, 138, 139] . Thus it appears that ICDs and apathy in PD, though representing opposite extremes of a continuum, are somehow related to the same brain structures and networks mediated by dopaminergic therapy [138, 140, 141] .
It remains a current hypothesis that DBS applied to the lateral STN region supports sensory-motor loops, whereas DBS applied to the medial STN influences ventral mesolimbic-nucleus accumbens-frontostriatal circuitry. Rodriguez-Oroz et al. [38] demonstrated that PD patients with ICDs and PD patients with severe motor dyskinesia secondary to STN DBS both display theta-alpha (4-10 Hz) activity, but at different frequencies. PD patients with ICDs thus display activity (mean peak at 6.71 Hz) 2-8 mm below the intercommissural line, whereas PD patients with dyskinesia display theta-alpha activity (mean peak at 8.38 Hz) 0-2 mm below the intercommissural line [38] . In PD patients with ICDs, cortico-subthalamic coherence was most frequent at 4-7.5 Hz in scalp electrodes placed at frontal regions anterior to the primary motor cortex. This indicates that activity stems from associativeprefrontal and emotional loops involved in cognitive and motivational processes mediated via frontal cortical innervations of the STN. However, it remains uncertain whether the activity upon STN stimulation relates to a reversed STN activation of the cortex or relates to the subcortical loops. In contrast, in PD patients with dyskinesia the cortico-subthalamic coherence was most frequent at 7.5-10 Hz in electrodes placed over the primary and supplementary motor areas. This suggests that the recorded activity in this group of patients stems from sensory-motor circuits regulating motor control and coordination [38] .
It seems obvious that the role of the STN in PD, on both a motor and cognitive level, still needs further investigations. Nevertheless, the STN clearly appears to be situated at an essential position within the basal ganglia playing a central role in not only sensorymotor loops, but also in associative-prefrontal and emotional circuits [14, 31, 38] . A relatively new target for DBS alleviating motor symptoms of PD, which has received increased attention in recent years, is the pedunculopontine nucleus (PPN) [142] [143] [144] . The PPN is a tegmental mesopontine nucleus composed of both cholinergic and non-cholinergic neurons with strong reciprocal connections to key output stations of the dorsal and ventral mesolimbic systems of the basal ganglia [142] . The subregions of the PPN are thus involved in the modulation and control of motor performance, attention, procedural learning, reinforcement, and reward processing [142, 145, 146] . Interestingly, deep brain stimulation in PPN, unlike STN DBS, has so far only been associated with the development of ICDs in PD in a single case [118] , making it a relevant target for future research.
THE ROLE OF THE NUCLEUS ACCUMBENS AND FRONTAL CORTEX IN ICDS IN PD
The ventral striatum, and in particular the nucleus accumbens, plays a pivotal role in ICDs and in emotional, cognitive, and addictive processes [147, 148] . It represents a crucial anatomical substrate within the neural networks involving the prefrontal, orbitofrontal, and associative-prefrontal cortical loops, which influence the essential dysfunctional elements present in PD patients with ICDs such as reward evaluation, reversal learning, impulsivity, and temporal discounting [94, 149, 150] . In the following we discuss the impact of these neuronal networks in relation to ICDs in PD based on different neuroimaging techniques.
Using functional magnetic resonance imaging (fMRI), Voon et al. [45] showed a decreased activity within the orbitofrontal cortex and the anterior cingulate cortex during risky decision-making in PD patients with ICDs. They demonstrated an association between dopamine agonists and increased sensitivity towards risk in PD patients with ICDs accompanied by a decreased activity in the ventral striatum. Likewise, Rao et al. [92] observed that PD patients with ICDs had a significantly reduced blood oxygenation level dependent (BOLD) activity in the right ventral striatum during risk taking compared to PD patients without ICDs. These results point at a bias towards risky choices in PD patients with ICDs, which might be the behavioral consequence of an impaired risk evaluation following dopamine agonist therapy [45] . In contrast, Voon et al. [96] demonstrated a dopamine agonist-induced increase in ventral striatum activity related to positive prediction error signifying a "better than expected" outcome in PD patients with ICDs potentially resulting in a reward bias. This effect was not seen in PD patients without ICDs. Additionally, PD patients with ICDs had an overall greater orbitofrontal cortex activity to gains and loss omissions and lower activity to losses than PD patients without ICDs [96] . Similarly, Frosini et al. [112] showed an increased BOLD response upon gambling cues bilaterally in the anterior cingulate cortex and in the left ventral striatum in PD patients with pathological gambling compared to PD patients without pathological gambling. In addition, this finding was associated with a cue-induced craving, which resembles that in individuals suffering from addiction [112] .
These discrepancies might be explained by differences in the used paradigms. Graef et al. [150] , recently showed that while levodopa improved PD patients' performance on an instrumental learning task with constant stimulus-reward contingencies depending on dorsal striato-frontal circuits, treatment impaired performance on a reversal learning task with varying reward contingencies relying on ventral striato-frontal loops. The findings by Graef et al. [150] support the "overdose hypothesis" assuming harmful effects of dopaminergic medication on reward evaluation and other cognitive functions depending on less affected brain regions in PD, such as the ventral striatum, and in particular the nucleus accumbens, in early disease stages [2] [3] [4] 150] . This hypothesis is further supported by van Eimeren et al.s [107] positron emission tomography (PET) findings of increased activity in the lateral orbitofrontal cortex, the rostral cingulate zone, the amygdala, and the external pallidum upon apomorphine intake in PD patients without pathological gambling while performing a probabilistic card game. In contrast, PD patients with pathological gambling showed the opposite reaction of apomorphine-induced deactivation of these brain regions resulting in impaired impulse control and response inhibition [107] . Moreover, using singlephoton emission computed tomography (SPECT), Cilia et al. [108] reported hyperactivity during rest in the orbitofrontal cortex, the hippocampus, the amygdala, the insula, and the ventral pallidum in PD patients with ICDs. They argued, that the abnormal resting state in the mesocorticolimbic circuit in this subgroup of patients provided additional support to the "overdose hypothesis" by suggesting a medication-induced overstimulation of the relatively intact reward-related neuronal networks [108] .
Functional PET studies of addiction and pathological gambling, have shown an abnormally enhanced phasic dopamine release in the ventral striatum in addicted individuals when confronted with cues of their addiction [20, 61, 62, 147, [151] [152] [153] [154] [155] . A similar dysfunctional dopaminergic response upon gambling has been shown in PD patients with comorbid pathological gambling [74] . Steeves and colleagues [74] , reported a lower baseline binding potential for the dopamine D 2 /D 3 radioligand [ 11 C]-raclopride in the ventral striatum of PD patients with pathological gambling compared to PD patients without pathological gambling and a relatively greater decrease in [ 11 C]-raclopride binding during gambling. This finding may suggest a relatively higher endogenous ventral striatal dopamine release upon gambling in PD patients with pathological gambling than in the PD control group. Similar findings of decreased [ 11 C]-raclopride binding in the ventral striatum and the caudate nucleus when exposed to rewarding versus neutral visual stimuli were reported by the team of O'Sullivan and Wu in PD patients with ICDs compared to PD controls [110, 111] indicating an enhanced endogenous dopamine release. In a SPECT study using the radiotracer FP-CIT, Cilia et al. [95] showed that PD patients with pathological gambling had a lower tracer binding in the ventral striatum compared to PD patients without gambling problems. According to Cilia et al. [95] , these results might reflect either a reduction of mesolimbic projections, or a lower dopamine transporter density combined with increased synaptic dopamine levels as previously suggested [74, 108] .
The findings in PD patients with ICDs translate to findings in both human and animal studies of addiction suggesting low baseline dopamine receptor availability to be associated with vulnerability of addiction [156] [157] [158] . Interestingly, low striatal dopamine receptor availability has also recently been demonstrated in individuals suffering from morbid obesity due to binge eating [159, 160] . Following this line of arguments, individuals with ICDs and other types of addictions, are likely to seek more potential rewarding events, e.g. the possible gains related to gambling, in order to compensate for a reward deficiency syndrome characterized by a chronic dopamine craving [74, 161] . However, Joutsa et al. [162] very recently argued that a striatal dopamine release during gambling irrespective of out-come in fact challenges this hypothesis, which predicts blunted mesolimbic dopamine responses to gambling in pathological gamblers. Thus according to this argument, the findings by Voon et al. [45] and Rao et al. [92] support the reward deficiency hypothesis, whereas the findings by Voon et al. [96] , Frosini et al. [112] and Steeves et al. [74] contradict the hypothesis. The expectation of receiving a reward seems to be enough to induce a striatal dopamine release in PD patients with pathological gambling, which is also seen in pathological gamblers without PD [151, 152, 162] . Moreover, the experience of wanting or craving induced merely by visual gambling cues or following loss might serve as another hypothesis for explaining the observed striatal dopamine release [112] .
The processing of reward involves aspects of motivation, prediction, and pleasure, also referred to as the psychological components of "wanting", "learning", and "liking" [163, 164] . In addictive behaviors, wanting to a great extent equals craving. Recent studies have shown that even though individuals suffering from addiction do potentially get a dopaminergic enhancement from engaging in the addictive behavior, they might not feel any hedonic impact from the reward of the action. Exactly this is seen in a group of PD patients with DDS [79] . Using PET imaging, Evans et al. [79] demonstrated an increased dopamine release in the ventral striatum upon levodopa intake in PD patients with DDS, which correlated with the patients' subjective feelings of drug wanting (craving) but not liking [79] . This finding hints at liking and wanting components involving different neurotransmitter systems, where wanting seems closely related to the dopaminergic system, and liking seems associated with the opiate system [164] . In fact, the ability to learn to seek reward remains intact in rats lacking up to 99% of dopamine in the nucleus accumbens, they merely lack the motivation to use the skills they have learned [164] . Thus, consistent with the findings by Graef et al. [150] , one could argue that the reward system is not only a dopamine-driven system rather it includes a combination of a dopaminergic motivational part and an opioid dependent pleasure part.
In summary, the nucleus accumbens certainly seems to play a key role during the acquisition phase of addictive behaviors, whereas the dorsal striatum is particularly important in maintaining an addiction [147, 150, 165] . This transition seems to be facilitated by the direct D 2 /D 3 dopamine agonists on hypersensitive postsynaptic dorsal striatal dopamine receptors. Anatomically, the shift from initiation to consolidation of an addiction might reflect an equivalent shift from limbic to associative-prefrontal and sensory-motor circuits via the ventral tegmental area and the substantia nigra zona compacta dopaminergic ascending loops innervating the dorsal striatum [150, 165, 166] . The discussed findings highlight the importance of the orbitofrontal cortex, the anterior cingulate cortex, and the ventral striatum in risk evaluation, which is mediated by dopamine agonists in ICDs in PD. Thus, these findings might explain why dopamine agonists are important risk factors for developing ICDs in PD [45, 51, 167] . Furthermore, several studies show an altered dopaminergic activity within the ventral striatum in PD patients with concomitant ICDs resembling the dopaminergic activity observed in non-PD individuals suffering from other kinds of addiction. However, these issues are still not sufficiently investigated, and research suggests that dopamine and dopaminergic therapy are not the only agents that may impact the course of the disease. Other neurotransmitters are depleted in PD as well, and in the following we discuss the influence of serotonin in ICDs in PD.
THE ROLE OF SEROTONIN IN IMPULSE CONTROL DISORDERS IN PARKINSON'S DISEASE
It is obvious that dopamine agonists are not able to fully compensate for the natural physiological tonic/phasic release of dopamine or the inactivation by the re-uptake transporter following its release, since the dopaminergic nerve terminals are degenerated in PD. Among other important neurotransmitters depleted in PD is serotonin, whose impact on nonmotor manifestations of the disease is still subject to much debate [9] [10] [11] [12] . Furthermore, the possible role of a decrease in serotonergic activity in PD patients with ICDs with regard to impulsivity, response inhibition, and temporal discounting remains to be established. The serotonin innervations originating from the dorsal raphe nucleus supplies approximately 80% of the serotonergic innervation to the prefrontal and motor cortices as well as to the subcortical structures involved in PD (striatum, pallidum, STN, substantia nigra, and PPN) [168] . In PD, the role of serotonin is very important in relation to both ICDs and emotional disturbances associated with the disease, such as depression, apathy, and anxiety [10] . It is beyond the scope of this review to discuss the complex details regarding the interactions between dopamine and serotonin, since this topic has already been covered by excellent reviews [169] [170] [171] . Consequently, only a few highlights from the published literature will be discussed.
In conjunction with dopamine, serotonin seems to play an essential role in the modulation of impulse control, risk taking, and decision-making, and the activity of serotonin has been associated with enhanced reversal learning and attentional shifting, increased response inhibition, and decreased delay discounting [158, 170, [172] [173] [174] [175] [176] . Moreover, Campbell-Meiklejohn et al. [177] recently found that serotonin and dopamine complement each other in loss chasing (i.e. gambling to recover losses) in pathological gamblers. While serotonin activity seems related to persistent loss chasing, dopamine activity appears to regulate the magnitude of the losses being chased [177] . In addition, Long et al. [178] demonstrated that serotonin depletion shapes risky decision-making in macaque monkeys trained to perform a simple gambling task for rewards. Reducing serotonin synthesis resulted in a decreased preference for more conservative options in the gambling task, resulting in riskier decision-making in the monkeys. These findings introduce an important issue concerning the balance between high and low levels of serotonin leading to different, sometimes almost opposite, neural network activations and behavioral outcomes. Macoveanu et al. [175] recently demonstrated that high and low levels of serotonin had opposite effects on activity in the dorsomedial prefrontal cortex and the amygdala related to negative outcomes following low-risk decisions in a gambling task. In the dorsomedial prefrontal cortex, low levels of serotonin increased the negative outcome-related neural activity, whereas high levels of serotonin resulted in a decreased activity [175] . The opposite neural reaction to negative outcomes in the gambling task was present in the left amygdala, where high levels of serotonin led to increased activity relative to a decreased activity associated with low levels of serotonin [175] .
The balance between high and low levels of serotonin is furthermore implicated in impulsivity. Miyazaki et al. [176] demonstrated the importance of serotonin in temporal discounting through findings of increased serotonergic firing facilitating waiting behavior towards future rewards. These results suggest that in addition to the implications of dopamine depletion, low levels of serotonin, e.g. as a result of serotonergic degeneration in PD, might be essential in explaining the inability in PD patients with ICDs to wait for a reward and hence contributing to their maladaptive behavior.
To summarize, the presented results suggest that both the dopaminergic and the serotonergic systems are implicated in temporal discounting and risk-sensitive decision-making in general as well as in pathological gambling and other ICDs. Furthermore, the findings cautiously hint at potential dose-dependent pharmacological therapies for ICDs and addiction. Consistent with preclinical findings, a case study demonstrated a positive treatment response in a patient administered fluvoxamine to treat pathological gambling [179] . Whether similar selective serotonin reuptake inhibitors, or perhaps direct serotonergic agonists aiming at specific receptor subtypes, might ameliorate pathological gambling and other ICDs in early PD, perhaps at least in patients with comorbid depression, remains an open question for future research to address [49, 180] . In addition, it appears highly clinically relevant to further investigate how ICDs in PD impact the patients' daily functioning. In the following, we discuss cognitive impairments associated with ICDs in PD.
COGNITIVE SYMPTOMATOLOGY IN IMPULSE CONTROL DISORDERS IN PARKINSON'S DISEASE
Cognitive processes such as attention, planning, and anticipation are of ultimate importance in social interaction, learning, and decision-making [3, 4, 6, 181, 182] . It is well known that PD patients without ICDs experience cognitive difficulties in domains related to the fronto-striatal loops as their disease progresses [11-13, 28, 183, 184] . According to Hirano et al. [13] , the mesocortical dopamine system affected in PD is associated with executive functions and is mediated via levodopa medication and dopamine metabolism. Cholinergic impairment in PD is also implicated in attention and working memory and the role of acetylcholine in development of dementia is supported by acetylcholinesterase PET imaging [13] . Furthermore, research indicates that despite relatively preserved functions of the orbital and ventromedial prefrontal cortex in early disease stages, cognitive impairments might even occur in early PD, though most likely as a consequence of dopaminergic treatment [185, 186] . Below, we discuss findings based on a selection of cognitive tasks dependent on frontal cortical functions comparing PD patients with and without ICDs.
Executive functioning
The Stroop test and the Wisconsin Card Sorting Test represent two widely used tasks to evaluate executive functions. The Stroop test, which measures selective attention, cognitive flexibility, and speed of cognitive processing, has been associated with activation in the anterior cingulate cortex and the dorsolateral prefrontal cortex [187] . Similarly, the Wisconsin Card Sorting Test is a test of set shifting measuring cognitive flexibility. This test has been associated with activation of the dorsolateral prefrontal cortex as well as the ventrolateral prefrontal cortex and the caudate nucleus, which also modulate working memory functions [188] [189] [190] . Various studies have shown that PD patients perform poorly on both of these tests revealing a deficit in alteration or maintenance of a learned strategy based on task-dependent feedback and impaired impulse control regulation [183, 184, [191] [192] [193] [194] [195] . However, findings of preserved executive functions in PD exist as well, at least in early PD [196] .
In PD patients with concurrent ICDs, Vitale et al. [78] recently demonstrated deficits on executive tasks exploring cognitive flexibility and spatial planning. In addition, they noticed that the cognitive difficulties associated with ICDs in PD differed depending on the specific kind of ICD patients presented. PD patients with hypersexuality and multiple ICDs performed worse on verbal learning and memory tests compared to PD patients with pathological gambling [78] . Particularly, the PD patients with comorbid hypersexuality revealed more general cognitive deficits, poorer inhibitory control, and reduced immediate and delayed memory compared to PD patients with pathological gambling [78] . These findings suggest that hypersexuality in PD is associated with a more profound deficiency in the balance of the associative-prefrontal and emotional-limbic circuits than pathological gambling in PD. Additionally, compared to PD patients without pathological gambling, Santangelo et al. [123] reported impaired performance in PD patients with pathological gambling on cognitive tasks evaluating long-term memory and frontal lobe functions, including the Frontal Assessment Battery, phonological fluency, and the Trail Making Test. In contrast, Siri et al. [114] demonstrated preserved executive functions in PD patients with pathological gambling. Compared to PD patients without pathological gambling, patients with gambling problems revealed higher general cognitive abilities and performed better on attention and verbal fluency [114] .
Reversal and reinforcement learning
Closely related to cognitive flexibility is reinforcement and reversal learning, which has also been found to be compromised in PD, at least in medicated patients [186, 197] . Reversal learning impairments appear to be particularly pronounced following treatment with the dopamine D 2 /D 3 receptor agonist pramipexole [3, 198, 199] . In line with our previous discussion of the functional neuroanatomy of ICDs in PD, the results on cognitive impairments in PD might be explained by a treatment-induced disruption of functional activity within the nucleus accumbens, which is involved in alteration of behavioral strategy. Interestingly, Cools et al. [148] demonstrated that reversal learning was in fact accompanied by increased nucleus accumbens activity only in medicated PD patients. Current neuroanatomical studies strongly suggest that the modulatory influence on cognition via the nucleus accumbens appears to be mediated by its upstream neuronal looping through the ventral pallidum and thalamic projections to the frontal cortex [166, 200] . Furthermore, the aforementioned fMRI study by Voon et al. [96] demonstrated that dopamine agonists increase the rate of learning from gain and enhanced ventral striatal activity to positive prediction error in PD patients with ICDs, an effect that was not present in PD patients without ICDs. In contrast, dopamine agonists induced a decrease in learning from loss in PD patients without ICDs but not in PD patients with ICDs [96] . Lastly, PD patients with ICDs had greater orbitofrontal cortex activation upon gains relative to lower activation upon losses compared to PD patients without ICDs both on and off medication [96] . However as previously discussed, Graef et al. [150] showed that dopaminergic treatment affects tasks implicating diverse neuronal networks differently.
Decision-making under ambiguity
A wide range of cognitive tasks is designed to examine decision-making. Among these are the Iowa Gambling Task, the Cambridge Gambling Task, the Game of Dice Task, the Balloon Analogue Risk Task, and the Beads Task, which are all associated with the limbic-orbitofrontal-striatal loop [201] . The Iowa Gambling Task is most often used to measure decisionmaking under ambiguous scenarios with implicit rules and it is known that patients with deficits in the orbitofrontal and ventromedial prefrontal cortex and the amygdala perform poorly on this task [201] [202] [203] . Also, PD patients have revealed impaired performance on the Iowa Gambling Task [97, 194, 196, [204] [205] [206] [207] [208] and this has even been found in early disease stages despite preserved executive functions [196] . In contrast, Euteneuer et al. [201] observed intact Iowa Gambling Task performance in PD patients without ICDs in spite of impaired performance on the Game of Dice Task and executive dysfunctions. Furthermore, Bentivoglio et al. [97] recently reported that compared to PD patients without ICDs, PD patients with ICDs tend to lose more money and make more risky decisions on the task resembling the performance of pathological gamblers without PD [151, 152] .
Djamshidian et al. [113] investigated decisionmaking under ambiguity in PD patients with and without ICDs using the Beads Task, which assesses reflective impulsivity under ambiguous conditions [209] . Overall, PD patients made more impulsive decisions than controls, reflecting a tendency in PD patients to make rapid decisions based on insufficient information [113] . A similar trend has been associated with DBS in STN. Frank et al. [44] showed that STN DBS interferes with the normal capacity to slow decisionmaking processes down when faced with ambiguous decision-making scenarios. In fact, they found that PD patients with DBS made more hasty decisions under high-conflict conditions [44] .
Decision-making under risk
Decision-making under risk requires intact dorsolateral prefrontal cortex activity [6, 201] and can be assessed using the Game of Dice Task and the Cambridge Gambling Task, on which PD patients have shown poor performance [5, 201, 210, 211] . In particular, medicated patients seem to be impaired on these tasks, as suggested by Torta et al. [211] who found that patients receiving higher doses of dopaminergic medication performed worse and were more impulsive than patients receiving lower treatment doses.
Another way of measuring risky decision-making is by using the Balloon Analogue Risk Task [212] , in which loss aversion has been associated with increased anterior cingulate cortex activity, whereas increased ventromedial prefrontal cortex activity has been associated with reward seeking [213] . In PD patients, this task seems to be modulated by dopaminergic medication, at least in PD patients with concurrent ICDs. Claassen et al. [51] recently demonstrated that dopamine agonists increased risk taking in PD patients with ICDs on this task, whereas no effect of dopamine agonists on risk taking was observed in PD patients without ICDs.
Temporal discounting
Temporal discounting refers to a preference towards more immediate rewards and a parallel devaluation of delayed rewards, a clinical finding very common in individuals suffering from ICDs and addictions. Just a few years ago, Voon et al. [75] linked dopamine agonist medication to an elevated delay discounting in PD patients with pathological gambling and compulsive buying relative to PD patients without ICDs. Furthermore, PD patients with ICDs revealed more working memory deficits than PD controls [75] . Interestingly, in another study Voon et al. [80] demonstrated increased impulsive decision-making in PD patients with compulsive buying and pathological gambling, but not in patients with binge eating or hypersexuality. Housden et al. [214] presented a similar finding in PD patients with comorbid ICDs indicating an inability to wait for a reward despite intact reward learning [149, 214] . Overall, these findings suggest that a tendency in PD patients with ICDs towards devaluation of delayed rewards, though differences across ICDs might exist. Furthermore, the disinhibited behavior appears to be enhanced by dopamine agonists and strongly associated with an elevated preference for immediate over future rewards [75, 80, 149, 214] .
In summary, the aspects of cognition discussed above are highly relevant in PD since patients often suffer significant impairments as the disease progresses and following prolonged treatment. The issue of executive and decision-making dysfunctions associated with ICDs in PD is far from resolved, but it appears that a common feature for cognitive deficits associated with ICDs in PD involve disturbances in impulsivity, temporal discounting, cognitive flexibility, and reinforcement and reversal learning that is particularly related to the ventral striatum and the frontal cortex [13] . Nevertheless, inconsistent findings reinforce the need for additional studies to determine whether ICDs in PD are accompanied by further cognitive deficits and whether different ICDs are associated with different behavioral and cognitive profiles in PD.
CONCLUSIONS AND PERSPECTIVES
We have reviewed the literature from the past 12 years reporting ICDs in PD and conclude that a continuously growing number of studies support the concept of treatment-induced ICDs in PD. Both pharmacological and surgical therapies have been associated with the development of ICDs. Particularly, the direct D 2 /D 3 dopamine agonists appear to be linked to this behavioral complication. Furthermore, we have argued that both the subthalamic nucleus and the nucleus accumbens play key roles in ICDs, potentially leading to serious consequences for the individual on financial, interpersonal, and cognitive levels. However, to fully understand why ICDs affect up to 15.5% of PD patients, it is not enough to consider the contributions of the dopaminergic system. Additional neurotransmitters need to be taken into account. We highlighted the impact of serotonin in the non-motor manifestations of PD and touched upon the role of opioids in addictive behaviors, since both neurotransmitters seem to be important mediators in reward processing and risk evaluation.
Despite an increasing interest in the field, we lack sufficient knowledge regarding therapy in ICD symptomatology in PD. Thus, there is a great need for future research to take a closer look at the functional neuroanatomy of ICDs and related cognitive deficits as evaluated by PET [74, 79, 82, 105, 107, 110, 111] , SPECT [94, 95, 108] , fMRI [45, 92, 96, 112] , or MEG studies [215] in order to fully understand why PD patients appear to be at greater risk of developing ICDs than the general population. We have argued that both the orbitofrontal and anterior cingulate cortices and the ventral striatum are linked to impaired risk evaluation, which is mediated by dopamine agonists in PD patients suffering from comorbid ICDs. This serves as just one possible explanation of why dopamine agonists are among important risk factors for developing ICDs in PD [45, 51] . Another possible explanation is related to the "overdose hypothesis" and attributes the cognitive deficits in PD patients with ICDs to the depleted caudate nucleus, and the dorsal striatum in general, altering the cognitive functions associated with the prefrontal cortex. This is then further compromised as the relatively intact ventral striatum in early PD is overdosed by dopaminergic treatment.
Likewise, an important step for future research is to assess how ICDs and other non-motor manifestations of PD affect the daily functioning and psychological well-being of the patients. Potentially, this could lead to faster identification of PD patients at risk for developing ICDs and improved management of adverse effects of treatment. A recent study demonstrated that in PD patients with ICDs symptom severity and related psychiatric disturbance improved following cognitive-behavioral therapy, unfortunately without relieving caregiver distress or burden markedly [216, 217] . It is important in this regard to emphasize that the detection of ICDs relies very much on caregivers, who play an important role in the daily medical care and supervision of psychiatric symptoms following withdrawal of dopamine agonists [53, 98, 216, 218] . Still, reduction of dopamine agonists is the primary strategy in managing ICDs in PD, but it is often associated with the development or worsening of depression, anxiety, or apathy, which have been found to occur in up to 19% of patient during dopamine agonist withdrawal [219] . Pharmacological management of ICDs in PD has received increasing attention in recent years and several different compounds have been scientifically tested. Among these are zonisamide [220] and donepezil [221] , which are used to treat cognitive impairments and dementia in PD [222] . Also valproate, which is traditionally used to treat e.g. epilepsy, anorexia nervosa, anxiety, and bipolar disorders, has been shown effective in treating both pathological gambling in non-PD patients and ICDs in PD [34, 223] . Other possible candidates include selective serotonin reuptake inhibitors, at least in the subgroup of patients with ICD who displays comorbid depressive symptoms, the noradrenaline reuptake inhibitor atomoxetine, which is sometimes prescribed to patients with ADHD, since this compound leaves the ventral striatal dopamine system intact; and the opioid antagonist nalmefene [224, 225] . Undoubtedly, it is an important topic for future studies to investigate this in more detail, since mixed results have been reported so far [226, 227] . Additionally, future research should investigate whether dopamine agonist with an extended release are associated with ICDs as well, or whether these compounds could serve as an alternative to the more short-acting dopamine agonists in preventing the increased risk of developing ICDs in PD [226] . 
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